mvabea
janssen-cilag international n.v. - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - la fiebre hemorrágica, el Ébola - vacunas - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - leucemia-linfoma linfoblástica de células precursoras - agentes antineoplásicos - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
haemocomplettan p 1g cápsula blanda
scienza uruguay - cápsula blanda - fibrinógeno humano 1 g inyectable
fibryga 1 g comprimido recubierto
megalabs uruguay s.a. - comprimido recubierto - fibrinógeno humano 1 g inyectable
hemonor 5000 ui/ml solucion inyectable
nordic pharmaceutical company s.a.c. - droguerÍa - heparina sódica - solucion inyectable - 5000ui/ml - por vial 1.00 ml - - heparina
hemonor 1000 ui/ml solucion inyectable
nordic pharmaceutical company s.a.c. - droguerÍa - heparina sódica - solucion inyectable - 1000ui/ml - por pastilla - - heparina
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - agentes antineoplásicos - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
heparina sódica solución inyectable 25.000 ui/5 ml
ascend laboratories s.p.a. - heparina - sin formulas
heparina sódica solución inyectable 5000 u.i./ 5 ml
ascend laboratories s.p.a. - heparina - sin formulas